172 related articles for article (PubMed ID: 12140378)
1. Decline in MHC class I expression with increasing thickness of cutaneous melanomas in standard-strain transgenic mouse models.
Milling SW; Silvers WK; Sai T; Mintz B
Melanoma Res; 2002 Jun; 12(3):221-30. PubMed ID: 12140378
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
Milling SW; Sai T; Silvers WK; Mintz B
Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
[TBL] [Abstract][Full Text] [Related]
3. MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.
Kim TS; Cohen EP
Cancer Immunol Immunother; 1994 Mar; 38(3):185-93. PubMed ID: 8124687
[TBL] [Abstract][Full Text] [Related]
4. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.
Smahel M; Síma P; Ludvíková V; Marinov I; Pokorná D; Vonka V
Vaccine; 2003 Mar; 21(11-12):1125-36. PubMed ID: 12559790
[TBL] [Abstract][Full Text] [Related]
5. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
6. Melanocyte culture lines from Tyr-SV40E transgenic mice: models for the molecular genetic evolution of malignant melanoma.
Larue L; Dougherty N; Bradl M; Mintz B
Oncogene; 1993 Mar; 8(3):523-31. PubMed ID: 8382353
[TBL] [Abstract][Full Text] [Related]
7. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.
Orlow SJ; Hearing VJ; Sakai C; Urabe K; Zhou BK; Silvers WK; Mintz B
Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10152-6. PubMed ID: 7479744
[TBL] [Abstract][Full Text] [Related]
8. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
10. Transgenic mouse model of malignant skin melanoma.
Mintz B; Silvers WK
Proc Natl Acad Sci U S A; 1993 Oct; 90(19):8817-21. PubMed ID: 8415613
[TBL] [Abstract][Full Text] [Related]
11. Impairment of the melanogenic pathway in B16 melanoma cells transfected with class I H-2 genes.
Prezioso JA; Hearing VJ; Muller J; Urabe K; Wang N; Gorelik E
Melanoma Res; 1995 Feb; 5(1):15-25. PubMed ID: 7734952
[TBL] [Abstract][Full Text] [Related]
12. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of melanoma-associated antigen expression and ecotropic retrovirus production in B16BL6 melanoma cells transfected with major histocompatibility complex class I genes.
Li M; Muller J; Xu F; Hearing VJ; Gorelik E
Cancer Res; 1996 Oct; 56(19):4464-74. PubMed ID: 8813142
[TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma in transgenic mice.
Bradl M; Klein-Szanto A; Porter S; Mintz B
Proc Natl Acad Sci U S A; 1991 Jan; 88(1):164-8. PubMed ID: 1846036
[TBL] [Abstract][Full Text] [Related]
15. Enhanced MHC class I and costimulatory molecules on B16F10 cells by Ganoderma lucidum polysaccharides.
Sun LX; Lin ZB; Duan XS; Lu J; Ge ZH; Li XF; Li XJ; Li M; Xing EH; Song YX; Jia J; Li WD
J Drug Target; 2012 Aug; 20(7):582-92. PubMed ID: 22697491
[TBL] [Abstract][Full Text] [Related]
16. Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy.
Le Fur N; Kelsall SR; Silvers WK; Mintz B
Proc Natl Acad Sci U S A; 1997 May; 94(10):5332-7. PubMed ID: 9144237
[TBL] [Abstract][Full Text] [Related]
17. Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo.
Rall GF; Mucke L; Oldstone MB
J Exp Med; 1995 Nov; 182(5):1201-12. PubMed ID: 7595191
[TBL] [Abstract][Full Text] [Related]
18. Differential induction of H-2K versus H-2D class I major histocompatibility antigens by recombinant gamma interferon. Lack of Kk augmentation in a leukemia virus-induced tumor is due to a cis-dominant effect.
Green WR; Rich RF; Beadling C
J Exp Med; 1988 May; 167(5):1616-24. PubMed ID: 3130455
[TBL] [Abstract][Full Text] [Related]
19. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Restifo NP; Marincola FM; Kawakami Y; Taubenberger J; Yannelli JR; Rosenberg SA
J Natl Cancer Inst; 1996 Jan; 88(2):100-8. PubMed ID: 8537970
[TBL] [Abstract][Full Text] [Related]
20. MHC class I up-regulation protects some but not all targets against LAK-mediated lysis: possible implications for the existence of LAK cell subpopulations using different recognition strategies.
Sarin A; Haridas V; Saxena RK
Immunol Lett; 1993 Sep; 38(1):59-62. PubMed ID: 8300155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
